Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OM 8980

Drug Profile

OM 8980

Alternative Names: Escherichia coli extract (ECE) - Vifor Pharma; OM 89; OM-8980; SolcoUrovac; Subreum; Uro-Vaxom

Latest Information Update: 04 May 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OM Pharma
  • Developer Apsen Farmaceutica; Eurolab Especialidades Medicinales de Eurofar; Tosse Pharmaceuticals; Vifor Pharma
  • Class Antirheumatics; Bacterial vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis; Urinary tract infections
  • No development reported Prostatitis
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 06 Dec 2012 Invida is now called Menarini Asia-Pacific
  • 11 Nov 2011 Invida Group has been acquired by Menarini
  • 09 Sep 2009 OM Pharma has been acquired and merged into Vifor Pharma
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top